NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: UMIN000001295

Registered date:04/08/2008

Phase I trial of CHP-HER2-pulsed dendritic cell vaccine for advanced breast and non-small cell lung cancer

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedbreast cancer, non-small cell lung cancer
Date of first enrollment2006/02/01
Target sample size9
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)subcutaneous injection of CHP-HER2-pulsed dendritic cells each cell dose, 0.3x10E7, 1x10E7, 3x10E7 four doses every two weeks three subjects for each cell dose, dose-escalating study

Outcome(s)

Primary Outcomeadverse effect profiles, including events, frequency and grades.
Secondary OutcomeHER2-specific immune responses anti-tumor effects

Key inclusion & exclusion criteria

Age minimum20years-old
Age maximum75years-old
GenderMale and Female
Include criteria
Exclude criteriaPregnancy, contra-ceptive during trial entry. Milking. Serious bleeding tendency. Risk of thrombosis. Acitive infection, HIV, HCV and HBV-positives. Serious pleural effusion, ascites and pericardial effusion. Probable alternative drug treatment during the trial.

Related Information

Contact

public contact
Name Masaki Miyamoto1), Fumiaki Tanaka2)
Address Japan
Telephone
E-mail m-miyamo@med.hokudai.ac.jp
Affiliation Hokkaido University Hospital1), Kyushu University Beppu Medical Center2) Department of Surgery1,2)
scientific contact
Name Takashi Nishimura, Satoshi Kondo, Masaki Mori
Address Kita-15-Jo, Nishi-7, Kita-ku, Sapporo, Hokkaido, 3-1-1, Tshurumihara, Tsurumi, Beppu, Oita, Japan Japan
Telephone
E-mail
Affiliation Hokkaido University, Institute for Genetic Medicine1), Hospital1Hokkaido University Hospital2), Kyushu University Hospital at Beppu3) Division of Immunoregulation1), Department of Surgery2,3)